Method of treating allergic diseases

FIELD: medicine.

SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.

EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.

1 ex

 

The invention relates to the field of medicine may be used in the treatment of allergic diseases.

Currently in therapy of allergic diseases use enterosorption - extracting and removing from the intestines of toxins and allergens using sorbing substances.

There is a method of treatment of allergies, including oral administration of powdered mineral zeolite with the degree of dispersion of from 0.1 to 3 mm in the form of an aqueous suspension of a daily dose of 0.5 g per 1 kg of body weight within 15-45 days [patent RU 2116791, 1998].

There is a method of treatment of atopic dermatitis, characterized in that the biologically active points affect EHF waves and infrared radiation, in addition, appoint an elimination enterosgel therapy at a dose of 10-15 3 times a day for 10 days [patent RU 2199304, 2003].

The closest analogue of the invention is a method of treatment of asthma and chronic obstructive bronchitis, which consists in the fact that conduct bacteriological examination of faeces and sputum (if necessary induced). The selected allochthonous bacteria determine the sensitivity to bacteriocins of strains-producers of probiotic "BioMarin" method perpendicular strokes on the NS Yegorov. In the case of sensitive enteric bacteriocins and pantropic is acteri at the first stage within 10 days daily take per os no 2 doses of probiotic "BioMarin": in the morning 1 hour before Breakfast and in the evening after 3 hours after dinner ("overnight"). This provides selective decontamination of the gut against pathogenic and conditionally pathogenic bacteria, as well as hematogenous translocation strains-producers of "Bioperine in inflammation in the bronchial tree to suppress the development of pantropic microflora. The second stage of bacteriotherapy includes the combined use of in the course of 10 days per os biologically active additives "Liquid concentrate of bifidobacteria and probiotic "Colibacterin" 500 and 1 dose, respectively, for 1 hour before Breakfast and 3 hours after dinner [patent RU 2224530, 2004]. It provides reinforcement of the effect of selective decontamination of the gut, as well as the colonization of the large intestine strains-producers entered the second phase of probiotics. The disadvantages of this method are the following: "Liquid concentrate of bifidobacteria" contains natural milk, which is an additional antigen sensitized to the body and is produced only in, Novosibirsk, the method has only antibacterial orientation without cleansing the body from antigens, toxins, antibodies. In addition, provided colonization by bifidobacteria is inefficient, because there is no pre intestinal colonization by lactobacilli. How complicated bacteriological studies of faeces and ocracy, you can use the method with sensitivity of allochthonous bacteria to bacteriocins of strains-producers of probiotic "BioMarin". As stated by the applicant, modification or replacement of selected bacterial preparations, under the conditions of the sequence of introduction of the developed two-step scheme, as well as their dosage does not provide the claimed positive effect of treatment of bronchial asthma and chronic obstructive bronchitis.

The technical result when using the invention - improving therapeutic effect due to the elimination of the body's endogenous and exogenous toxic substances of different nature in sensitized body, deep cleaning of the intestines from the products of fermentation, putrefaction, pathogenic and conditionally pathogenic flora, natural stimulation of biological processes and modulation of the immune system, replacement of pathological microflora on normal.

This technical result is achieved in that in the method of treatment of allergic diseases, which includes cleansing and colonization of the mucosa of the gastrointestinal tract by bacteria, according to the invention for the purification of the body is injected in the morning on an empty stomach ½ daily dose of the enteric daily for 1-3 months for 2-3 hours before eating, and then to colonize the gastro-Kish is knogo tract normal flora daily for 4 weeks administered orally 3 times daily liquid bio-complex Normoflorin in age, dosage, in the first and second methods of drug use Normalien L, and the third - Normalien B.

The proposed method for the treatment of allergic diseases is carried out as follows. Treatment of concomitant diseases of the digestive system (chronic cholecystitis, pancreatitis, gastritis, giardiasis and other), rehabilitation of chronic foci of infection. Patients are given advice on creating Allergy-free life (termination or maximum decrease of contact with the allergen), adherence to a strict diet. For removing antigens, antibodies administered in the morning on an empty stomach ½ daily dose of the enteric within 1-3 months for 2-3 hours before eating, and then to colonize the gastrointestinal tract normal flora daily for 4 weeks orally 3 times per day of liquid bio-complex Normoflorin in age, dosage, and the first and second methods of drug use Normalien L, and the third - Normalien B: taken by mouth 1 hour before a meal, immediately shake before use, dilute 1:3 any food liquid is not higher than 37°C.

The application of the enteric fasting and before meal helps its maximum on the intestinal wall (diffusion of endogenous toxins). The use of enterosorbent during the day in several stages between meals and promotes the binding is of the food bolus or chyme, the decrease in osmotic sorption activity on the intestinal wall. A long application of the enteric allows purification of the body from antigens and prevent allergic reactions for a long time than you can get a desensitizing effect. Through the use of enterosorbent 1 time per day it can be used for a long time, because during the day the epithelium of the intestine, saliva, gastric juice, bile, pancreatic juice, the juice of the jejunum and ileum, hormones, regulatory peptides, prostaglandins, etc. etc. during the day will be to perform its functions. POLYSORB has sorption, detoxification, antioxidant and membrane-stabilizing properties. Reduces metabolic stress on the organs of detoxification and excretion, improves the humoral environment and immune status.

Chelators in the lumen of the gastrointestinal tract bind and remove from the body of endogenous and exogenous toxic substances of different nature (pathogenic bacteria and bacterial toxins, food allergens, antigens, antibodies, drugs and poisons, heavy metals, radionuclides, alcohol), due to diffusion are sorbed products of metabolism (bilirubin, urea, cholesterol and lipid complexes), the metabolites responsible for the development of endogenous toxicosis, in which Chechnya irritate the receptor area and improve circulation. The use of enterosorbent gives us the opportunity to cleanse the body as a whole, which is important when polyvalent Allergy desensitizing effect against many types of allergens.

Bifido - and lactobacteria normalize physiological, biochemical, immunological processes in the organism. Normofloriny have: antimicrobial and antioxidant activity, colonization resistance, immunokorrigiruyuschy action, detoxification effect, the ability of optimization of metabolic processes, stimulation of anti-infective resistance, anti-tumor activity. Bacteria Normoflorins L and B are biologically active, start working from the first minute of contact with the mucous membrane, creates a protective biofilm on the mucous membrane of the digestive tract, protecting from viruses, bacteria, fungi, protozoa, remain available for colonization potential to affect different parts of the immune system, regulating, and non-specific cellular and humoral immunity, stimulate the phagocytic activity of neutrophils, macrophages, synthesis of immunoglobulin A and participate in the formation of interferon, are able to suppress the production of Ig E, then there is a natural immunomodulator and reduce the sensitization of the body, affect the chemical composition of mucus, reduce the indicate the concentration of inflammatory mediators. Product domestic production antagonistically active in relation to conditionally pathogenic and pathogenic flora of Russia.

The importance of elimination of drugs from the treatment of allergic diseases caused by the fact that the experience there is the case of anaphylactic shock on an antihistamine (diphenhydramine) when providing first aid for anaphylactic shock caused by lidocaine. In the proposed method there is no toxic and immunosuppressive effects of pharmaceuticals.

The invention is illustrated by the following example. Patient ACR, born in 1999, he complained: atopic dermatitis of the hands up to the elbow bends, toe to knee bends, facial, exacerbation of obstructive bronchitis 4-5 times a year, year-round allergic rhinitis, food Allergy: could take only corn and buckwheat porridge, meat rabbit. After protivogelmintnoe and protivolyamblioznye treatment effect was not observed. Treatment: in the morning on an empty stomach took 1 tablespoon to the top of POLYSORB, dissolved in ½ Cup of water, daily for 3 months for 2-3 hours before eating, and then daily for 4 weeks orally 3 times a day taken liquid bio-complex Normoflorin 1 tablespoon first and second methods of drug Normalien L, and the third - Normalor the n B: inside 1 hour before a meal. When viewed in 4 months: skin clean, notes the disappearance of the symptoms of allergic rhinitis in 1 month after application of POLYSORB, no complications obstructive bronchitis at Ari, a significant expansion of food range. After treatment by passing the examination in the Clinic of children's diseases GOU VPO Moscow Medical Academy named after I.M. Sechenov all skin Allergology, blood tests for allergen specific IgE were negative.

The method of treatment of allergic diseases, which includes cleansing and colonization of the mucosa of the gastrointestinal tract by bacteria, characterized in that the purification of the body is injected in the morning on an empty stomach ½ daily dose of the enteric daily for 1-3 months for 2-3 hours before eating, and then to colonize the gastrointestinal tract normal flora daily for 4 weeks administered orally 3 times daily liquid bio-complex Normoflorin in age, dosage, and the first and second methods of drug use Normalien L, and the third - Normalien B.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.

EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.

8 cl, 2 ex, 2 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.

EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.

7 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, particularly to method of treatment of dermatological allergic state. Proposed method comprises injection of efficient amount of [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-silt][7-fluorine-1-(2-metoxyethyl)-4-trifluorometoxy-1H-indol-3-il]methanon or its appropriate N-oxide, pharmaceutically acceptable salt or solvate.

EFFECT: higher efficiency.

5 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to an agent for preventing and/or treating an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma, which is a low-molecular polysulphated hyaluronic acid derivative.

EFFECT: obtaining a low-molecular polysulphated hyaluronic acid derivative.

15 cl, 103 dwg, 17 tbl, 55 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns preparing a fast-acting effective and safe agent for treating rhinitis. Solving the problem provides the agent for treating rhinitis, particularly allergi rhinitis containing C-type natriuretic peptide (CNP) and/or B-type natriuretic peptide (BNP) as an active ingredient.

EFFECT: invention provides the notable health improvement in rhinitis, particularly in allergic rhinitis, and besides, the therapeutic effect, ensures fast and prolonged action, and gives no local side effects.

21 cl, 7 ex, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using a composition containing galactooligosaccharide, fructooligosaccharide and uronic acid oligosaccharide in preparing a composition for oral administration into an infant for preventing the local administration of corticosteroids and/or preventing the administration of a calcineurin inhibitor into the above infant, wherein uronic acid oligosaccharide represents a pectin degradation product and/or an alginate degradation product, and wherein using the corticosteroids and/or administering the calcineurin inhibitor is applicable for treating eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis and intertrigo. Particularly, the composition is a nutritional composition.

EFFECT: what is shown is reducing probability of the local administration of corticosteroids and dermatological preparations to be required for the purpose of preventing the above skin diseases, or reducing the length of using the corticosteroids.

5 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to naphthalene carboxamide derivatives of general formula I which possess the properties of protein kinase or histone deacetylase inhibitors. The compounds can find application for preparing a drug for treating inflammatory diseases, autoimmune diseases, oncological disease, diseases of the nervous system and neurodegenerative diseases, allergies, asthma, cardiovascular diseases and metabolic diseases or disease related to hormonal diseases. In general formula I: , Z represents CH or N; each of the groups R1, R2 and R3 represents hydrogen, halogen, alkyl, alkoxy or trifluoromethyl; R4 represents or X represents a benzene ring or a pyridine ring; R5 represents one or more substitutes specified in a group consisting of hydrogen, halogen, alkyl, alkoxy or trifluoromethyl. The invention also refers to a method for preparing the above compounds, a pharmaceutical preparation and using them.

EFFECT: preparing the compounds which possess the properties of protein kinase or histone deacetylase inhibitors.

13 cl, 10 tbl, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a complex of biologically active substance for treating allergic diseases of various genesis, characterised by the fact that it has been recovered from cod liver oil by gradual fractionation from ballast lipids by extraction in a two-phase oil and water extractant, centrifugation and ultrafiltration or diafiltration through a material with separation limit 25 kDa, and contains peptides 30-55%, amino acids 40-65%, carbohydrates 2-8%, micro and macroelements 2-13%.

EFFECT: invention provides the drug spectrum broadening.

8 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel of 2,4-pyrimidine diamine compounds of formula I, which inhibit degranulation of immune cells and can be used in treating cell reactions mediated by FcεRI or FcγRl receptors. In formula (I) each R2 and R4 is independently phenyl substituted with one or more R8 groups or a heteroaryl selected from a group consisting of , where the heteroaryl is optionally substituted with one or more R8 groups and at least one of R2 and R4 is a heteroaryl; R5 is selected from a group consisting of (C1-C6)alkyl, optionally substituted with one or more identical or different R8 groups, -ORd, -SRd, fluorine, (C1-C3)halogenalkyloxy, (C1-C3)perhalogenalkyloxy, -NRcRc, (C1-C3)halogenalkyl, -CN, -NO2, -C(O)Rd, -C(O)ORd, -C(O)NRcRc, -C(NH)NRcRc, -OC(O)Rd, -OC(O)ORd, -OC(O)NRcRc; -OC(NH)NRcRc, - [NHC(O)]nORd, R35 is hydrogen or R8; each Y is independently selected from a group consisting of O, S and NH; each Y1 is independently selected from a group consisting of O, S and NH; each Y2 is independently selected from a group consisting of CH, CH2, S, N, NH and NR37. Other values of radicals are given in the claim.

EFFECT: improved efficiency.

19 cl, 6 tbl.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 2-S-benzylpyrimidine derivatives having CRTH2 receptor antagonist activity. In formula 1: R1 means -CO2H; R4a and R4b mean hydrogen; W means -C(O)NR7-; R2 and R3, each independently mean F; Cl; Br;-NR10R11 or (C1-C6)alkoxy, optionally substituted by 1-3 halogen atoms; R5 means hydrogen; R6 means (C1-C6)alkyl; (C6-C19)aryl or (5-15)-member heteroaryl containing nitrogen, oxygen or sulphur atoms as heteroatoms, wherein above aryl and heteroaryl are optionally substituted by one or more substitutes specified in a group consisting of halogen; (C1-C6)alkyl optionally substituted by 1-3 halogen atoms; and (C1-C6)alkoxy optionally substituted by one, two or three halogen atoms; R7 means hydrogen; R10 and R11, each independently mean (C1-C6)alkyl; or R10 and R11, together with N, whereto attached form a 3-8- member saturated or unsaturated ring optionally containing one or more O or S atoms, or one or more additional N atoms in the ring; k is equal to 0; m is equal to 1.

EFFECT: invention also refers to using the above compounds for preparing a drug for treating allergic and inflammatory diseases mediated by CRTH2 receptor activity, such as asthma, atopic dermatitis, allergic conjunctivitis, Churg-Strauss disease, sinusitits, basophilic leukaemia, and recurrent urticaria.

27 cl

FIELD: biotechnology.

SUBSTANCE: strain Bacillus lentus "GKPM-Obolensk" B-7150 - producer of bacteriocin-like substance of broad spectrum of antimicrobial action is proposed, having molecular weight according to data of SDS-PAGE of about 4 kDa. Also the method of obtaining bacteriocin-like substance is provided, comprising submerged cultivation of Bacillus lentus "GKPM-Obolensk" B-7150 at a temperature 29-30°C in carbohydrate-yeast medium based on inorganic source of amino nitrogen with a limit of oxygen and carbohydrate. Isolation of bacteriocin-like substance from acellular fluid is carried out using dichloromethane or silica gel type adsorbent, and from the surface of cells - using ethanol. Then the fractions are combined and dried.

EFFECT: strain has antagonistic activity against coliform and other gram-negative bacteria and some species of gram-positive microorganisms.

2 cl, 3 dwg, 5 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. The bacterial system is intended for normalising microbiocenosis of a human or animal organism. The system comprises a support which is a carbon-mineral enterosorbent (enterumin), eubiotic bacteria (bifidobacteria) immobilised thereon and nutrient components and a protective medium. The carbon-mineral enterosorbent is modified by oxidative treatment (with hydrogen peroxide) and the bacteria titre in the finished preparation is 1 x 107 KOE/g of the bacterial system.

EFFECT: invention increases functional and colony-forming activity of eubiotic bacteria and increases sorption capacity thereof.

3 cl, 3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and concerns treating the patients suffering oncological diseases by administering the preparations inducing active cellular immune stimulation. The preparations are administered in the form of lyophilised lysate of gram-positive enteric bacteria enclosed in gelatine capsules. That is combined with correcting intestinal dysbacteriosis, administering antioxidants, vitamins and minerals, as well as nutrient-enriched protein food, amino acid L-arginine, and pectin- and fibre-enriched vegetable food.

EFFECT: method provides higher clinical effectiveness of the patients suffering the oncological diseases with no side effects.

4 ex

FIELD: biotechnology.

SUBSTANCE: strain Lactobacillus fermentum RCM B-2793D is proposed, which has antagonistic activity against pathogenic and opportunistic microorganisms. Also the consortium of strains of Lactobacillus fermentum RCM B-2793D, Lactobacillus crispatus VKM B-2727D, Lactobacillus gasseri VKM B-2728D, Lactobacillus plantarum VKM B-273D is proposed, which has probiotic action and is used for production of bacterial preparations and lactic acid products of functional nutrition. The consortium has a higher antagonistic activity against pathogenic and opportunistic microorganisms compared to individual strains of lactobacilli in its composition.

EFFECT: group of inventions enables to expand the range of probiotic strains, the means for prevention and treatment of mastitis in breastfeeding mothers.

2 cl, 1 dwg, 5 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. There are presented strain Enterococcus faecium 8G-1 (NRRL B-50173), strain Enterococcus faecium 8G-73 (NRRL B-50172) and strain Bacillus pumilus 8G-134 (NRRL B-50174) providing the improvement in ruminant's health. Any of the above strains or a combination thereof in a combination with monensin are used to prepare a formulation providing the improvement in ruminant's health. There are also presented versions of the method for the improvement in ruminant's health involving administering the above strains either alone, or in a combination with monensin as well. What is also provided is a method for producing a microorganism administered into ruminants.

EFFECT: group of inventions can be used for treating or preventing acidosis, for improving ruminant's health indicators and/or ensuring higher productiveness.

18 cl, 8 dwg, 11 tbl, 4 ex

FIELD: packaging industry.

SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.

EFFECT: invention enables to extend the shelf life of the probiotic product.

13 cl, 1 dwg, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to medical microbiology, and can be used for treating intestinal yersiniosis, or pseudotuberculosis, or salmonellosis experimentally. That is ensured by simulating one of the above pathologies in experimental animals followed by oral administration of therapeutic preparations in therapeutically effective doses with controlling the content of pathological microflora for a period of time providing elimination of the disease. Stimbifid or a culture fluid of lactic acid bacilli is administered orally as the therapeutic preparation into each animal for the first 2 hours after infection once a day as a monotherapeutic preparation promoting the colonisation resistance of the intestinal mucosa to an agent. Stimbifid is administered into each animal in a dose of 13 mg for 5 days from the moment of the infection, while the culture fluid is administered in an amount of 0.2 ml throughout 7 days from the moment of the injection. What is also presented is a method for preparing an agent for treating intestinal yersiniosis, or pseudotuberculosis, or salmonellosis experimentally.

EFFECT: group of inventions provides a high percentage of pathology elimination by using the prebiotic preparation and the liquid probiotic complex with no accompanying negative consequences.

4 cl, 3 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to functional food products and represents a method for production of a non-aqueous health-improving product that is administrated in the form of drops and contains strain of lactic bacteria suspended in vegetable food oil; vegetable food oil is mixed with vitamin D; Lactobacillus rhamnosus GG lactic bacteria are suspended in the produced oil mixture.

EFFECT: invention ensures combination of beneficial effects of the proposed composition ingredients and easiness of the latter dosing during intake.

11 cl, 1 dwg, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml.

EFFECT: invention improves therapeutic efficacy in chronic and latent endometritis.

3 tbl, 3 ex

FIELD: biotechnology.

SUBSTANCE: strain Lactobacillus acidophilus No. 9-PS has biochemical activity and high acidity. The strain is deposited in the Departmental collection of beneficial microorganisms for agricultural purposes of Russian Agricultural Academy (RCAM) under the registration number of RCAM01850. The strain may find application in prevention and correction of disorders of microbiocenosis of the gastrointestinal tract.

EFFECT: invention enables to increase growth of mucous cultures of lactic acid bacteria and accelerates the process of colonisation of intestinal with beneficial microflora.

2 tbl, 3 ex

Phosphate adsorbent // 2527682

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a pharmaceutical composition for phosphate adsorption in a body and/or from biological fluids when administered orally or externally, and to a biologically active food additive. The pharmaceutical composition and the biologically active food additive contains a physical mixture or a combination of powders, granules, crystals or chips of calcium, magnesium or iron salts in a certain mole relation of Ca2+, Mg2+ and Fe3+. The concentration of Ca+2 is 80 mg - 2,400 mg; the concentration of Mg+ is 49 mg - 729 mg and the concentration of Fe+3 is 112 mg - 1,676 mg in a daily dose.

EFFECT: invention provides effective binding of phosphate in a wide range of pH levels causing no overdosage of the consumed phosphate-binding compounds and enabling avoiding the related side effects.

20 cl, 10 dwg, 5 tbl, 16 ex

Up!